ISMJ

Background: There is growing evidence that supports oxidized LDL particles may have an ability to inhibit osteoblastic activity, and increase osteoclastic activity; hence these particles may lead the balance to osteoporosis. However, the relationship between oxidized LDL and osteoporosis has not been investigated in human studies yet. The main aim of the current population-based cohort study was to investigate the correlation between serum levels of oxidized LDL and bone mineral density (BMD) among postmenopausal women.

Materials and methods: A total of 378 healthy, postmenopausal women were randomly selected from 13 clusters in the port city of Bushehr, Iran. Serum levels of  oxidized LDL, MDA-oxidised LDL,  osteoprotegerin (OPG), the receptor activator of nuclear factor kappa B ligand (RANKL), CrossLaps, and osteocalcin were measured using enzyme-linked immunosorbent assay methods. Bone mineral density (BMD) was measured at the femoral neck and lumbar spine at baseline and at follow-up 5.8 years later.

Results: Annual bone loss was 0.82 % at the femoral neck and 3.55% at the lumbar spine among the women. No significant correlation was found among circulating MDA- oxidised LDL, antibodies against oxidised LDL and biomarkers of bone metabolism (P>0.05). There was no correlation between MDA- oxidised LDL, antibodies against oxidised LDL and BMD at all anatomic sites (P>0.05). In logistic regression analysis, neither oxidized LDL levels nor antibodies against oxidized LDL predicted incident lumbar or spine osteoporosis 5.8 years later.

Conclusion: Neither serum levels of MDA-oxidized LDL nor antibodies against oxidized LDL was associated with BMD at the lumbar or femoral neck area.  Neither serum levels of oxidized LDL levels nor circulating antibodies against oxidized LDL predicted incident osteoporosis in postmenopausal women.